Broadcasting News

Lee Soo-hyuk Withdraws from "Men of the Harem" Mid-Series

"Scheduling Issues" "Lee Jong-won's Appearance Is Under Discussion"

Gim Ga Yeong
2026-08-19 11:05:54
[Edaily Starin Gim Ga Yeong Reporter] Actor Lee Soo-hyuk has left the cast of “Men of the Harem.”
Lee Soo-hyuk (Photo: News1)
On the 19th, a representative from Studio Dragon told E-Daily, "Lee Soo-hyuk has left *Men of the Harem* due to scheduling conflicts."
“Men of the Harem” is based on the Naver web novel by author Alpha Tart. It is a palace romance fantasy that follows the story of Empress Latil of the Empire as she brings in male concubines to secure her hold on the imperial throne.
Studio Dragon is producing the series, with director Lee Eung-bok—known for *Descendants of the Sun*, *Goblin*, *Mr. Sunshine*, and *Sweet Home*—at the helm, and writer Hwang Jin-young (*Lovers*) serving as the screenwriter.
Suzy has been cast as the lead character, Latil. Lee Soo-hyuk was originally scheduled to appear as one of Latil’s male concubines. The cast also includes Shin Seung-ho, Dex, Kim Dan, and Yoo Jung-hoo.
Meanwhile, while there were reports that Lee Jong-won would take over the role vacated by Lee Soo-hyuk, Studio Dragon stated that the matter is “under discussion.”

Economy

Corporation

IT·Science

Economy

NEXTBIOMEDICAL CO., LTD., Which Made Its Mark Globally with NexPowder, Named a “KOSDAQ Rising Star” for the Second Consecutive Year

#NEXTBIOMEDICAL CO., LTD., a company specializing in innovative medical devices, has been named to the Korea Exchange’s “KOSDAQ Rising Star” list for the second consecutive year, once again demonstrat…
2026-08-19 10:02:44

Corporation

Celltrion, Buoyed by Direct Sales, Expands into Asia’s Pharm-Emerging Markets... Solidifies No. 1 Position and Prepares New Drugs

Celltrion(068270)Celltrion is strengthening its market dominance in Asia—a leading “Shinhung” (emerging pharmaceutical) market—by leveraging its unrivaled direct-to-market competitiveness. While its f…
2026-08-19 09:54:02

IT·Science

LGCHEM,LTD Begins Preclinical Trials for ‘GNV205,’ an Immunotherapy Drug Based on Genube Technology

# LGCHEM,LTD is set to begin preclinical research on “GNV205,” an antibody-cytokine fusion candidate acquired from the domestic biotech firm GenuV. The company plans to develop it as a next-gen…
2026-08-19 10:20:03